Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 205

1.

Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles.

Bulner S, Prodeus A, Gariepy J, Hynynen K, Goertz DE.

Ultrasound Med Biol. 2019 Feb;45(2):500-512. doi: 10.1016/j.ultrasmedbio.2018.10.002. Epub 2018 Nov 15.

PMID:
30447880
2.

Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial.

Traboulsee AL, Machan L, Girard JM, Raymond J, Vosoughi R, Hardy BW, Emond F, Gariepy JL, Bone JN, Siskin G, Klass D, Isserow S, Illes J, Sadovnick AD, Li DK.

Neurology. 2018 Oct 30;91(18):e1660-e1668. doi: 10.1212/WNL.0000000000006423. Epub 2018 Sep 28.

3.

A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo.

Prodeus A, Sparkes A, Fischer NW, Cydzik M, Huang E, Khatri I, Young A, Woo L, Chow CW, Gorczynski R, Gariépy J.

Mol Ther Nucleic Acids. 2018 Sep 7;12:350-358. doi: 10.1016/j.omtn.2018.05.023. Epub 2018 Jul 3.

4.

Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.

Fischer NW, Prodeus A, Gariépy J.

JCI Insight. 2018 Aug 9;3(15). pii: 121364. doi: 10.1172/jci.insight.121364. [Epub ahead of print]

5.

Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome.

Fischer NW, Prodeus A, Tran J, Malkin D, Gariépy J.

J Natl Cancer Inst. 2018 Dec 1;110(12):1418-1421. doi: 10.1093/jnci/djy114.

PMID:
29955864
6.

Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells.

Abdul-Wahid A, Cydzik M, Fischer NW, Prodeus A, Shively JE, Martel A, Alminawi S, Ghorab Z, Berinstein NL, Gariépy J.

Int J Cancer. 2018 Oct 15;143(8):1963-1977. doi: 10.1002/ijc.31586. Epub 2018 Aug 9.

7.

Severe cerebellar hemorrhage following transverse sinus stenting for idiopathic intracranial hypertension.

Lavoie P, Audet MÈ, Gariepy JL, Savard M, Verreault S, Gourdeau A, Milot G, Carrondo Cottin S.

Interv Neuroradiol. 2018 Feb;24(1):100-105. doi: 10.1177/1591019917734389. Epub 2017 Oct 9.

PMID:
28992723
8.

VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses.

Prodeus A, Abdul-Wahid A, Sparkes A, Fischer NW, Cydzik M, Chiang N, Alwash M, Ferzoco A, Vacaresse N, Julius M, Gorczysnki RM, Gariépy J.

JCI Insight. 2017 Sep 21;2(18). pii: 94308. doi: 10.1172/jci.insight.94308. [Epub ahead of print]

9.

Glypican-6 promotes the growth of developing long bones by stimulating Hedgehog signaling.

Capurro M, Izumikawa T, Suarez P, Shi W, Cydzik M, Kaneiwa T, Gariepy J, Bonafe L, Filmus J.

J Cell Biol. 2017 Sep 4;216(9):2911-2926. doi: 10.1083/jcb.201605119. Epub 2017 Jul 10.

10.

Prognostication in critically ill patients with severe traumatic brain injury: the TBI-Prognosis multicentre feasibility study.

Turgeon AF, Lauzier F, Zarychanski R, Fergusson DA, Léger C, McIntyre LA, Bernard F, Rigamonti A, Burns K, Griesdale DE, Green R, Scales DC, Meade MO, Savard M, Shemilt M, Paquet J, Gariépy JL, Lavoie A, Reddy K, Jichici D, Pagliarello G, Zygun D, Moore L; TBI-Prognosis Study Team and the Canadian Critical Care Trials Group.

BMJ Open. 2017 Apr 17;7(4):e013779. doi: 10.1136/bmjopen-2016-013779.

11.

Individual differences in the activity of the hypothalamic pituitary adrenal axis: Relations to age and cumulative risk in early childhood.

Holochwost SJ, Gariépy JL, Mills-Koonce WR, Propper CB, Kolacz J, Granger DA.

Psychoneuroendocrinology. 2017 Jul;81:36-45. doi: 10.1016/j.psyneuen.2017.03.023. Epub 2017 Mar 24.

PMID:
28411412
12.

Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial.

Olson MC, Maciel A, Gariepy JF, Cullors A, Saldivar JS, Taylor D, Centeno J, Garces JA, Vaishnavi S.

Prim Care Companion CNS Disord. 2017 Mar 16;19(2). doi: 10.4088/PCC.16m02036.

13.

p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.

Fischer NW, Prodeus A, Malkin D, Gariépy J.

Cell Cycle. 2016 Dec;15(23):3210-3219. Epub 2016 Oct 18.

14.

Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.

Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R.

Cancer Immunol Res. 2016 Oct;4(10):881-892. Epub 2016 Sep 7.

15.

Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network.

Samuel N, Wilson G, Id Said B, Pan A, Deblois G, Fischer NW, Alexandrova R, Casallo G, Paton T, Lupien M, Gariepy J, Merico D, Hudson TJ, Malkin D.

Oncotarget. 2016 Aug 2;7(31):49611-49622. doi: 10.18632/oncotarget.10417.

16.

A Specific Population of Reticulospinal Neurons Controls the Termination of Locomotion.

Juvin L, Grätsch S, Trillaud-Doppia E, Gariépy JF, Büschges A, Dubuc R.

Cell Rep. 2016 Jun 14;15(11):2377-86. doi: 10.1016/j.celrep.2016.05.029. Epub 2016 Jun 2.

17.

Patterns of joint parasympathetic, sympathetic, and adrenocortical activity and their associations with temperament in early childhood.

Kolacz J, Holochwost SJ, Gariépy JL, Mills-Koonce WR.

Dev Psychobiol. 2016 Dec;58(8):990-1001. doi: 10.1002/dev.21429. Epub 2016 May 10.

PMID:
27163558
18.

Induction of antigen-specific TH 9 immunity accompanied by mast cell activation blocks tumor cell engraftment.

Abdul-Wahid A, Cydzik M, Prodeus A, Alwash M, Stanojcic M, Thompson M, Huang EH, Shively JE, Gray-Owen SD, Gariépy J.

Int J Cancer. 2016 Aug 15;139(4):841-53. doi: 10.1002/ijc.30121. Epub 2016 Apr 15.

19.

Slow binding kinetics of secreted protein, acidic, rich in cysteine-VEGF interaction limit VEGF activation of VEGF receptor 2 and attenuate angiogenesis.

Cydzik M, Abdul-Wahid A, Park S, Bourdeau A, Bowden K, Prodeus A, Kollara A, Brown TJ, Ringuette MJ, Gariépy J.

FASEB J. 2015 Aug;29(8):3493-505. doi: 10.1096/fj.15-271775. Epub 2015 Apr 28.

PMID:
25921830
20.

Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers.

Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariépy J.

Mol Ther Nucleic Acids. 2015 Apr 28;4:e237. doi: 10.1038/mtna.2015.11.

Supplemental Content

Loading ...
Support Center